Incidence was modeled with Enzalutamide clinical trial Poisson regression using generalized estimating equations with a robust variance adjustment for within-child correlation. Incidence rate ratios (IRR) were computed and vaccine efficacy (VE) computed as (1-IRR) with corresponding CIs. For dichotomous variables (e.g. medication use, hospital visitation), proportions of home visits with

a positive response were compared between groups and the 95% CI was calculated using the Cornfield method [19]. All analyses were done in Stata, version 11 (Stata Corporation, College Station, TX.) To calculate the number of cases prevented by PRV, we subtracted the incidence rate among the PRV group from the incidence among placebo recipients for a given outcome, and standardized to 100 person-years. To calculate the percentage of severe gastroenteritis episodes reported at home that were caused by rotavirus, we divided the vaccine efficacy for gastroenteritis with severe dehydration at the home visit by the vaccine efficacy for severe RVGE from the clinic-based catchment surveillance.

The protocol and consent forms were approved by the Western Institutional Review Board (WIRB), the National Ethical Review Committee of the Kenya Medical Research Institute, and the Institutional Review Board of CDC. Written informed consent was obtained from each participant’s parent or guardian before enrollment and HIV-testing. Of 1308 study participants screened and randomized, 656 were assigned to the PRV group and Apoptosis Compound Library in vitro 652 to the placebo group (Fig. 1). The per-protocol efficacy analysis included 86% Thiamine-diphosphate kinase of randomized participants (86% vaccinated, 86% placebo). The median follow-up time among the per-protocol population in the clinic-based catchment surveillance was 480 days (IQR 209–540) for vaccine group, and 492 days (IQR 205–551) for placebo group. The study groups were similar in sex and age at each vaccine dose (Table 1). Less than a quarter of participants received all three doses of PRV/placebo concomitantly with oral poliovirus vaccine (OPV). Among randomized infants at enrollment, 1158 (88.5%) were tested

for HIV infection; 38 (3.3%) were HIV-infected – based on PCR – 21 (3.6%) PRV recipients and 17 (2.9%) placebo recipients. Eight additional participants became HIV-infected after enrollment during the follow-up period. A total of 33 cases of RVGE occurred, of which 19 (57.6%) were severe and included in the primary per-protocol efficacy analysis (Table 2). Severe RVGE was identified in 5 (0.88%) evaluable PRV children receiving vaccine and in 14 (2.5%) evaluable children receiving placebo during the entire follow-up period of nearly 2 years, yielding incidence rates of 1.0 and 2.7 per 100 person-years, respectively. Efficacy against severe RVGE through the entire study period was 63.9% (95% CI: −5.9,89.8).